-

Kronos Bio Announces Participation in the Jefferies Virtual Healthcare Conference

SAN MATEO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kronos Bio, Inc., dedicated to drugging transcriptional regulatory networks in cancer, today announced that Norbert Bischofberger, Ph.D., President and Chief Executive Officer will present at the Jefferies Virtual Healthcare Conference taking place June 2-4, 2020.

Presentation Date: Wednesday, June 3, 2020
Presentation Time: 4:30 PM ET

A webcast will be made available on the Company's website at www.kronosbio.com in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

About Kronos Bio

Kronos Bio, Inc. is dedicated to drugging transcriptional regulatory networks in cancer. We leverage deep capabilities in computational biology, chemical biology and clinical translational expertise in order to map transcriptional regulatory networks in cancer, identify vulnerabilities and screen for small molecule modulators.

For more information, please visit www.kronosbio.com or follow the company on LinkedIn.

Contacts

Kronos Bio Contact:
Christopher Wilfong
Chief Operating Officer
media@kronosbio.com

Industry:

Kronos Bio, Inc.

Details
Headquarters: San Mateo, CA
CEO: Norbert Bischofberger
Employees: 40
Organization: PRI
Release Versions
English

Contacts

Kronos Bio Contact:
Christopher Wilfong
Chief Operating Officer
media@kronosbio.com

More News From Kronos Bio, Inc.

Kronos Bio Appoints Elena Ridloff, CFA, to Board of Directors

SAN MATEO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kronos Bio, Inc., a private clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced that the company has appointed Elena Ridloff, CFA, to its Board of Directors, where she will serve as Chair of the Audit Committee. Ms. Ridloff brings nearly 20 years of experience in the biopharmaceutical s...

Kronos Bio Announces $155 Million Private Financing

SAN MATEO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kronos Bio, Inc., a private clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription, today announced a private financing of approximately $155 million of convertible notes, with $148 million in funding received to date and the remaining $7 million to be funded by mid-Se...

Kronos Bio Appoints Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development

SAN MATEO, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kronos Bio, Inc., a private clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription, today announced the appointment of Yasir Al-Wakeel, BM BCh, as the company’s Chief Financial Officer and Head of Corporate Development. “Yasir brings a diverse set of capabilities that...
Back to Newsroom